Jump to Footer

Seth T. Housman

Clinical Assistant Professor, Infectious Diseases
Department of Pharmacy Practice

Email:     seth.housman@wne.edu
Phone:   413-796-2426
Office:    CSP 428

 
Seth T Housman received his Doctor of Pharmacy and Master of Public Administration degrees from Drake University in Des Moines, Iowa. He then completed an ASHP-accredited PGY-1 Pharmacy residency at Baystate Medical Center in Springfield, MA and during this time served as adjunct assistant professor at MCPHS University – Worchester/Manchester. Following residency, Dr. Housman completed a two-year Infectious Diseases Pharmacotherapy fellowship at the Center for Anti-Infective Research and Development (CAIRD) at Hartford Hospital in Hartford, CT. Prior to his arrival at WNE College of Pharmacy, Dr. Housman was the Associate Director, Clinical and Developmental Pharmacology at CAIRD in Hartford, CT. Dr. Housman served as adjunct assistant professor at the University of Connecticut School of Pharmacy during his tenure at CAIRD.

Dr. Housman’s research interests include optimizing antimicrobial dosing through the use of pharmacokinetic and pharmacodynamic principles and strategies to overcome antimicrobial resistance. He has authored a number of peer-reviewed publications and presented at several national and international conferences. Dr. Housman is a member of the Infectious Diseases Society of America, the Society of Infectious Diseases Pharmacists, the American College of Clinical Pharmacy, the American Society of Health Systems Pharmacists, and the American Society for Microbiology.
 

Teaching

  • IPC Infectious Diseases 1
  • IPC Infectious Diseases 2
  • Compounded Sterile Preparations Laboratory
     

Research/Scholarship

Dr. Housman’s research interests include optimizing antimicrobial dosing through the use of pharmacokinetic and pharmacodynamic principles and strategies to overcome antimicrobial resistance. He has authored a number of peer-reviewed publications and presented at several national and international conferences.
 

Recent Publications

  • Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014; 44(3): 235-41.

  • MacVane SH, Housman ST, Nicolau DP. In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. Clin Pharmacol. 2014; 6: 97-101

  • Jain JG, Housman ST, Nicolau DP. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. J Antimicrob Chemother. 2014; 69(9): 2443-7.

  • Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Redican S, Nicolau DP. A Phase I, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women. Antimicrob Agents Chemother. 2014; 58(4): 2113-8.

  • Housman ST, Crandon JL, Nichols WW, Nicolau DP. Efficacy of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2014; 58(3): 1365-71.

  • Hagihara M, Housman ST, Nicolau DP, Kuti JL. In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014; 58(2): 672-7.

  • Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother. 2013; 57(11): 5679-83.

  • Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2013; 68(10): 2296-304.

  • Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy. 2013; 33(3): 266-74.

  • Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, Nicolau DP. Pulmonary disposition of tedizolid following once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012; 56(5): 2627-34.

  • Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP. Efficacy of human simulated exposure of ceftaroline against phenotypically diverse enterobacteriaceae isolates. Antimicrob Agents Chemother. 2012; 56(5): 2576-80.

  • Housman ST, Sutherland CA, Nicolau DP. In vitro evaluation of novel compounds against selected resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2012; 56(3): 1646-9.

  • Housman ST, Tessier PT, Nicolau DP, Kuti JL. Physical compatibility of telavancin with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2011; 68(23): 2265-70.

  • Housman ST, Kuti JL, Nicolau DP. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia. Clin Chest Med. 2011; 32(3): 439-50.

  • Housman ST, Kuti JL, Nicolau DP. Focus on ceftaroline: a novel cephalosporin with methicillin-resistant Staphylococcus aureus and multi-drug resistant Streptococcus pneumoniae activity. Formulary 2011; 46: 71-81.
     

Professional Affiliations

  • American Association of Colleges of Pharmacy
  • Infectious Diseases Society of America
  • American Society of Microbiologists
  • Society of Infectious Diseases Pharmacists
  • American College of Clinical Pharmacy
  • American Society of Health-System Pharmacists 
  • Phi Lambda Sigma National Pharmacy Leadership Society                    
  • Phi Delta Chi Pharmacy Fraternity                                                            
     

Practice Area

Baystate Medical Center
Infectious Diseases and Antimicrobial Stewardship